Why did VMD's Q2 earnings fall short of forecasts?

Lantern Pharma Inc's (LTRN) Q2 earnings fell short of forecasts due to several key factors: 1. **Increased Net Loss**: The company experienced a wider net loss of $5.9 million ($0.54 per share) in Q4 2024, up from $4.2 million ($0.39 per share) in the previous quarter. This significant increase in net losses indicates a deteriorating financial performance, which directly impacts the company's earnings and profitability. 2. **Revenue Decline**: The company's revenue also declined, with Q4 2024 revenue falling short of expectations. This decline in revenue, combined with the increase in net losses, has led to a shortfall in earnings. 3. **Operational Challenges**: Lantern Pharma Inc is facing operational challenges, including those related to its market position and competitive landscape. These challenges are likely impacting the company's ability to generate revenue and meet market expectations. In conclusion, Lantern Pharma Inc's (LTRN) Q2 earnings fell short of forecasts due to a combination of increased net losses and revenue decline. These factors, coupled with operational challenges, have resulted in a disappointing financial performance for the company.